CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 54 enrolled
Drug / intervention
Remdesivirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04582266
NCT04582266N/ACompleted
CompareCT.gov

Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States

National Institute of Allergy and Infectious Diseases (NIAID)·observational·Posted Oct 9, 2020·Updated Jun 9, 2023

In Brief

An observational study evaluating Remdesivir for COVID-19. Completed, enrolled 54 participants across 10 sites.

Detailed Summary

IMPAACT 2032 was a Phase IV prospective, open label, non-randomized opportunistic study. The objectives of this study were to describe the pharmacokinetic (PK) properties and safety of remdesivir (RDV) administered intravenously as part of clinical care among hospitalized pregnant and non-pregnant women of childbearing potential with coronavirus disease of 2019 (COVID-19). RDV was provided and managed by the participant's treating physician and was not provided as part of this study.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
CollaboratorsGilead Sciences

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedOct 9, 2020
Enrollment StartMar 31, 2021
Primary CompletionApr 13, 2022
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 5.7 years ago

Interventions

Remdesivirdrug

RDV was not provided as part of the study. Participants were administered RDV intravenously once daily for up to 10 days per clinical care.